Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Treatment and Management of Multiple Myeloma
Effective treatment and management of multiple myeloma requires a coordinated approach that blends the latest medical advances with individualized patient care. This page is designed for international patients and their families who are seeking clear, evidence‑based information about how multiple myeloma is treated at Liv Hospital in Istanbul. With a 10‑year survival rate now exceeding 50 % in many regions, early diagnosis and a comprehensive care plan are more critical than ever.
At Liv Hospital, a JCI‑accredited facility, patients benefit from a multidisciplinary team that includes hematologists, transplant specialists, radiologists, and supportive‑care professionals. The following sections detail each component of the therapeutic pathway—from initial induction regimens to long‑term follow‑up—so you can understand the options and make informed decisions about your health journey.
Whether you are newly diagnosed or exploring options after relapse, the information below outlines the full spectrum of treatment and management strategies available, including cutting‑edge immunotherapies, stem cell transplantation, and supportive care measures that enhance quality of life.
Understanding Multiple Myeloma and Defining Treatment Goals
Multiple myeloma is a cancer of plasma cells that accumulate in the bone marrow, disrupting normal blood formation and causing bone lesions, anemia, and kidney dysfunction. The primary objectives of treatment and management are to achieve deep remission, prolong survival, and preserve organ function while minimizing toxicity.
Key Clinical Milestones
- Induction response: Rapid reduction of tumor burden using combination chemotherapy.
- Consolidation: Strengthening the response with high‑dose therapy or transplant.
- Maintenance: Ongoing low‑intensity therapy to sustain remission.
Risk Stratification
Patients are categorized using the Revised International Staging System (R‑ISS), which incorporates serum β2‑microglobulin, albumin, LDH levels, and cytogenetic abnormalities. This stratification guides the intensity of treatment and management plans.
By aligning therapeutic intensity with disease risk, Liv Hospital ensures that each patient receives a tailored plan that balances efficacy with safety.
First‑Line Therapies and Modern Induction Regimens
Current first‑line treatment and management for transplant‑eligible patients typically combines a proteasome inhibitor, an immunomodulatory drug (IMiD), and dexamethasone. The most widely adopted regimen is VRd (bortezomib, lenalidomide, dexamethasone), which has demonstrated overall response rates above 90 %.
Standard Induction Options
- VRd – Bortezomib, lenalidomide, dexamethasone.
- KRd – Carfilzomib, lenalidomide, dexamethasone.
- Dara‑VTD – Daratumumab, bortezomib, thalidomide, dexamethasone.
Each regimen is administered in 21‑day cycles, with treatment duration ranging from 4 to 6 cycles before assessing response.
Choosing the Right Regimen
Selection depends on patient age, renal function, comorbidities, and cytogenetic risk. For example, patients with renal impairment may benefit from the non‑nephrotoxic profile of carfilzomib‑based combinations, while those with high‑risk cytogenetics might be steered toward daratumumab‑containing protocols.
Liv Hospital’s hematology team conducts comprehensive pre‑treatment assessments to ensure the chosen induction aligns with each patient’s unique health profile, forming a solid foundation for the subsequent phases of treatment and management.
Stem Cell Transplantation and Consolidation Strategies
High‑dose melphalan followed by autologous stem cell transplantation (ASCT) remains a cornerstone of curative‑intent treatment and management for eligible patients. ASCT deepens response, often converting partial remissions into complete remissions.
Transplant Eligibility
- Age ≤ 70 years (physiologic age more important than chronological).
- Adequate organ function—especially cardiac, pulmonary, and renal.
- No uncontrolled infections or severe comorbidities.
Procedure Overview
Patients first undergo stem cell mobilization using granulocyte‑colony stimulating factor (G‑CSF) with or without cyclophosphamide. Collected stem cells are cryopreserved, allowing the patient to receive high‑dose melphalan (140–200 mg/m²). After a short aplastic phase, the stored stem cells are reinfused, restoring marrow function within 10–14 days.
Consolidation and Maintenance
Following ASCT, consolidation therapy—often a short course of the same induction agents—helps eradicate residual disease. Maintenance, most commonly lenalidomide or ixazomib, is continued for up to two years or longer, depending on tolerance and disease status.
Liv Hospital’s transplant unit follows international guidelines, offering state‑of‑the‑art apheresis devices, strict infection control, and a dedicated recovery suite to optimize outcomes throughout the treatment and management continuum.
Targeted and Immunotherapy Options for Relapsed or High‑Risk Disease
When disease progresses despite initial therapy, newer targeted agents and immunotherapies become central to the treatment and management strategy. These drugs exploit specific molecular vulnerabilities of myeloma cells, offering high response rates even in heavily pre‑treated patients.
Monoclonal Antibodies
- Daratumumab – CD38‑directed, induces complement‑mediated cytotoxicity.
- Isatuximab – Another CD38 antibody with a distinct binding epitope.
- Elotuzumab – Targets SLAMF7, enhancing natural killer cell activity.
CAR‑T Cell Therapy
BCMA‑directed chimeric antigen receptor T‑cell therapy (e.g., ide‑cabtagene vicleucel) has shown overall response rates above 80 % in triple‑class refractory myeloma. Patients undergo leukapheresis, followed by lymphodepletion and infusion of engineered T cells.
Bispecific Antibodies
Agents such as teclistamab simultaneously bind BCMA on myeloma cells and CD3 on T cells, redirecting the immune response toward the tumor. Early‑phase trials report rapid and durable responses.
Liv Hospital participates in multiple international clinical trials, giving patients access to these breakthrough therapies as part of a comprehensive treatment and management plan.
Supportive Care, Monitoring, and Long‑Term Management
Successful treatment and management of multiple myeloma extends beyond anti‑myeloma drugs. Addressing bone health, infection risk, renal function, and psychosocial well‑being is essential for sustained quality of life.
Bone Disease Prevention
- Bisphosphonates (zoledronic acid) or denosumab to reduce skeletal‑related events.
- Regular imaging (whole‑body low‑dose CT or MRI) to monitor lesions.
Infection Prophylaxis
Vaccinations (influenza, pneumococcal, COVID‑19) are administered before therapy initiation. Antiviral prophylaxis (e.g., acyclovir) is standard when using proteasome inhibitors.
Renal Protection
Hydration protocols, avoidance of nephrotoxic agents, and early treatment of hypercalcemia help preserve kidney function throughout the disease course.
Psychosocial Support
Liv Hospital offers counseling, nutrition services, and physiotherapy to address fatigue, depression, and functional decline. A dedicated patient navigator assists with travel logistics, interpreter services, and accommodation, ensuring a seamless international experience.
Regular follow‑up visits, including serum free‑light chain assays and imaging, enable early detection of relapse, allowing timely adjustments to the treatment and management plan.
Why Choose Liv Hospital
Liv Hospital combines JCI accreditation with a dedicated international patient program, ensuring world‑class oncology expertise alongside seamless logistical support. Our hematology department leverages advanced diagnostics, state‑of‑the‑art transplant facilities, and participation in global clinical trials. International patients receive personalized coordination—including airport transfers, interpreter services, and comfortable accommodation—so they can focus entirely on their health.
Take the first step toward a personalized multiple myeloma care plan. Contact Liv Hospital’s International Patient Services today to schedule a virtual consultation and learn how our comprehensive treatment and management approach can support your journey.
Frequently Asked Questions
What are the main goals of multiple myeloma treatment?
Multiple myeloma treatment aims to achieve a deep and durable remission by reducing tumor burden, extending overall survival, and maintaining quality of life. Therapies are selected to eradicate malignant plasma cells, protect bone health, preserve kidney function, and avoid severe side effects. By balancing efficacy with safety, clinicians strive to keep patients active and reduce disease‑related complications such as fractures, anemia, and infections.
How is risk stratification determined for multiple myeloma patients?
The R‑ISS classifies patients into three stages based on serum β2‑microglobulin, albumin, lactate dehydrogenase (LDH) levels, and specific high‑risk cytogenetic abnormalities (e.g., del(17p), t(4;14)). Stage I indicates low‑risk disease with favorable markers, Stage II is intermediate, and Stage III reflects high‑risk biology. This stratification guides the intensity of induction, the need for early transplant, and eligibility for clinical trials, ensuring therapy is matched to disease aggressiveness.
What are the standard first‑line induction regimens for transplant‑eligible patients?
For patients who can undergo autologous stem cell transplantation, the most widely used induction protocols are VRd (bortezomib, lenalidomide, dexamethasone), KRd (carfilzomib, lenalidomide, dexamethasone), and Dara‑VTD (daratumumab, bortezomib, thalidomide, dexamethasone). These regimens are given in 21‑day cycles for 4–6 cycles before response assessment. Choice depends on age, renal function, comorbidities, and cytogenetic risk; for example, KRd is preferred in patients with renal impairment, while Dara‑VTD adds immune‑mediated killing for high‑risk disease.
When is autologous stem cell transplantation recommended?
Autologous stem cell transplantation (ASCT) is offered to patients who are physiologically fit, usually age 70 or younger, with sufficient cardiac, pulmonary, and renal reserve, and no uncontrolled infections. After induction, stem cells are mobilized with G‑CSF ± cyclophosphamide, collected, and cryopreserved. High‑dose melphalan (140–200 mg/m²) is then administered, followed by reinfusion of the stored cells, leading to rapid marrow recovery. ASCT deepens response, often converting partial remissions into complete remissions, and is followed by consolidation and maintenance to prolong disease control.
What targeted therapies are available for relapsed or high‑risk multiple myeloma?
For patients whose disease progresses after initial therapy, newer agents focus on specific molecular targets. CD38‑directed antibodies such as daratumumab and isatuximab trigger immune‑mediated cell death. Elotuzumab targets SLAMF7 to activate natural killer cells. BCMA‑directed CAR‑T cell therapy (e.g., ide‑cabtagene vicleucel) shows >80 % overall response in triple‑class refractory disease. Bispecific antibodies like teclistamab bind BCMA on myeloma cells and CD3 on T cells, redirecting cytotoxic activity. These therapies are often delivered within clinical trials at Liv Hospital.
How does supportive care improve long‑term outcomes for myeloma patients?
Effective supportive care includes bisphosphonates or denosumab to prevent skeletal events, regular imaging to monitor lesions, vaccination and antiviral prophylaxis to reduce infections, and hydration plus avoidance of nephrotoxins to protect kidneys. Psychosocial services—counseling, nutrition, physiotherapy, and patient navigation—help manage fatigue, depression, and logistical challenges for international patients. By integrating these measures with anti‑myeloma therapy, patients experience fewer complications, maintain functional status, and achieve better long‑term survival.
What is the role of maintenance therapy after transplantation?
After autologous stem cell transplantation, maintenance therapy is given to sustain the depth of response achieved. Lenalidomide is the most common agent, administered daily for up to two years or longer if tolerated, while ixazomib offers an oral proteasome inhibitor alternative. Clinical trials have shown that maintenance reduces the risk of relapse and extends progression‑free survival. Choice of agent depends on prior exposure, side‑effect profile, and patient preference, and therapy is adjusted based on tolerability and disease monitoring.
